Technical Analysis for OVID - Ovid Therapeutics Inc.

Grade Last Price % Change Price Change
F 3.67 -0.81% -0.03
OVID closed down 0.81 percent on Wednesday, August 4, 2021, on 35 percent of normal volume.
Earnings due: Aug 9
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical OVID trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
20 DMA Resistance Bearish -0.81%
Bollinger Band Squeeze Range Contraction -0.81%
Outside Day Range Expansion -0.81%
Bollinger Band Squeeze Range Contraction -1.61%
Narrow Range Bar Range Contraction -1.61%
NR7 Range Contraction -1.61%
Bollinger Band Squeeze Range Contraction -1.61%
200 DMA Resistance Bearish -2.39%
Older End-of-Day Signals for OVID ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 14 hours ago
60 Minute Opening Range Breakdown about 15 hours ago
Possible Inside Day about 16 hours ago
10 DMA Resistance about 19 hours ago
20 DMA Resistance about 19 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ovid Therapeutics Inc. Description

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Disorders Symptoms Neurological Disorders Epilepsy Syndromes Takeda Pharmaceutical Company Urological Disorders Genodermatoses Fragile X Syndrome Sedatives Anticonvulsants Rare Neurological Disorders

Is OVID a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.37
52 Week Low 2.25
Average Volume 671,764
200-Day Moving Average 3.86
50-Day Moving Average 4.06
20-Day Moving Average 3.77
10-Day Moving Average 3.74
Average True Range 0.15
ADX 16.53
+DI 18.84
-DI 25.38
Chandelier Exit (Long, 3 ATRs) 3.65
Chandelier Exit (Short, 3 ATRs) 4.03
Upper Bollinger Bands 3.94
Lower Bollinger Band 3.60
Percent B (%b) 0.2
BandWidth 9.11
MACD Line -0.08
MACD Signal Line -0.09
MACD Histogram 0.0033
Fundamentals Value
Market Cap 232.43 Million
Num Shares 63.3 Million
EPS -1.78
Price-to-Earnings (P/E) Ratio -2.06
Price-to-Sales 52.66
Price-to-Book 6.63
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.88
Resistance 3 (R3) 3.89 3.84 3.85
Resistance 2 (R2) 3.84 3.78 3.83 3.83
Resistance 1 (R1) 3.75 3.75 3.73 3.74 3.82
Pivot Point 3.70 3.70 3.68 3.69 3.70
Support 1 (S1) 3.61 3.64 3.59 3.60 3.52
Support 2 (S2) 3.56 3.61 3.55 3.51
Support 3 (S3) 3.47 3.56 3.50
Support 4 (S4) 3.46